IA-DATA

South-South Diagnostic Alliance Signs MOU with Biogenes Technologies as First Industry Partner

23 July 2025 | Media

South-South Diagnostic Alliance Signs MOU with Biogenes Technologies as First Industry Partner

By SSDxA

Kuala Lumpur, Malaysia – The South-South Diagnostic Alliance (SSDxA) is proud to announce the signing of a Memorandum of Understanding (MOU) with Biogenes Technologies Sdn Bhd, marking its first industry partnership. This milestone sets the foundation for a transformative collaboration aimed at developing diagnostic innovations tailored to the needs of endemic countries, starting with a focus on dengue.

The agreement underscores a shared commitment to shaping a new economic framework that supports businesses innovating diagnostic solutions for the Global South. Both parties will work together to leverage local expertise, improve access, and ensure the sustainability of diagnostic technologies across endemic regions.

Key areas of cooperation include:

  • Co-developing diagnostic needs and dengue-related innovation that align with the health priorities of endemic countries, led by local expertise.
  • Sustainable technology transfer and knowledge-sharing to build value chains within endemic countries, fostering local self-reliance.
  • Innovative pricing models to ensure that affordable diagnostics are prioritized and accessible in the public sector.
  • Regulatory alignment to ensure all products meet the safety and efficacy standards of endemic countries.
    Growing a regional industrial network built on shared values, local ownership, and a commitment to solving pressing public health challenges.
“This partnership with Biogenes marks a pivotal step in advancing the South-South Diagnostic Alliance’s mission to create locally-led, affordable, and sustainable diagnostic solutions,” said Jean-Michel Piedagnel, Director of SSDxA. “Together, we are working to ensure that innovation in diagnostics is no longer just imported — but homegrown, cost-effective, and responsive to the realities of our region.”

Biogenes Technologies, a Malaysia-based biotechnology company known for its innovation in diagnostics, aptamer & biosensor technology, shares SSDxA’s vision of enabling equitable health solutions across Malaysia and Southeast Asia.

“This collaboration reflects our collective belief in the utilization of science to advance technology which should serve local needs,” said Adrian Joseph, Co-founder & CEO of Biogenes. “We are honoured to partner with SSDxA, to identify and accelerate the development of impactful technologies that address real-world problems, starting with dengue.”
The MOU sets the stage for ongoing cooperation that centres regional leadership in health innovation and paves the way for future industry partnerships in support of equitable access to diagnostics.
Scroll to Top